ACADIA Pharmaceuticals Long Term Debt 2006-2021 | ACAD

ACADIA Pharmaceuticals long term debt from 2006 to 2021. Long term debt can be defined as the sum of all long term debt fields.
ACADIA Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2020 $
2019 $
2018 $
2017 $
2016 $0
2015 $
2014 $
2013 $0
2012 $
2011 $
2010 $
2009 $0
2008 $0
2007 $1
2006 $1
2005 $1
ACADIA Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31 $0
2016-09-30
2016-06-30 $0
2016-03-31 $0
2015-12-31
2015-09-30 $0
2015-06-30
2015-03-31 $0
2014-12-31
2014-09-30 $0
2014-06-30
2014-03-31
2013-12-31 $0
2013-09-30 $0
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $24
2009-06-30 $0
2009-03-31 $0
2008-12-31 $0
2008-09-30 $1
2008-06-30 $1
2008-03-31 $1
2007-12-31 $1
2007-09-30 $1
2007-06-30 $1
2007-03-31 $2
2006-12-31 $1
2006-09-30 $1
2006-06-30 $1
2006-03-31 $1
2005-12-31 $1
2005-09-30 $1
2005-06-30 $1
2005-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.978B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76